Prosecution Insights
Last updated: August 15, 2026

Dyne Therapeutics Inc.

6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
4
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (1)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (67%)
2
Easy (33%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§102 only1 (17%)
Double-patenting only2 (33%)
Double-patenting + other3 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
83% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
17% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
AEDER, SEAN E 1 56.9% +19.9%
BRETZ, COREY LANE 1 0.0% +0.0%
HUYNH, PHUONG N 1 65.7% +53.6%
ROSSI, JULIA ANNE LORRAIN 1 47.1% +60.0%
BERHANE, SELAM 1 59.0% +55.8%
BREEN, KIMBERLY CATHERINE 1 24.4% +56.7%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18270324 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY BRETZ, COREY LANE
17616870 METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES BREEN, KIMBERLY CATHERINE

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17796418 ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF BERHANE, SELAM 146d overdue
18017179 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES ROSSI, JULIA ANNE LORRAIN 22d
18024486 METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES HUYNH, PHUONG N 29d
18692415 DOSING OF MUSCLE TARGETING COMPLEXES FOR TREATING DYSTROPHINOPATHIES AEDER, SEAN E
17616870 METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES BREEN, KIMBERLY CATHERINE

Top Art Units

Art UnitApps
1635 1
1641 1
1615 1
1675 1
1657 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18692415 DOSING OF MUSCLE TARGETING COMPLEXES FOR TREATING DYSTROPHINOPATHIES AEDER, SEAN E §112DP Non-Final OA Pending Mar 15, 2024
18270324 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY BRETZ, COREY LANE 1635 DP Non-Final OA Pending Jun 29, 2023
18024486 METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES HUYNH, PHUONG N 1641 §102 Final Rejection 29d Pending Mar 02, 2023
18017179 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES ROSSI, JULIA ANNE LORRAIN 1615 DP Non-Final OA 22d Pending Jan 20, 2023
17796418 ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF BERHANE, SELAM 1675 §112DP Final Rejection 146d overdue Pending Jul 29, 2022
17616870 METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES BREEN, KIMBERLY CATHERINE 1657 §103§112DPOther Non-Final OA Pending Dec 06, 2021

Managing Dyne Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month